| Literature DB >> 15797993 |
Robert de Jonge1, Jan Hendrik Hooijberg, Bertrand D van Zelst, Gerrit Jansen, Gerritz Jansen, Christina H van Zantwijk, Christine H van Zantwijk, Gertjan J L Kaspers, Gert Jan L Kaspers, Godefridus J Peters, Frits G J Peters, Yaddanapudi Ravindranath, Rob Pieters, Jan Lindemans.
Abstract
We studied whether common polymorphisms in genes involved in folate metabolism affect methotrexate (MTX) sensitivity. Ex vivo MTX sensitivity of lymphoblasts obtained from pediatric patients with acute lymphoblastic leukemia (ALL; n = 157) was determined by the in situ thymidylate synthase inhibition assay after either continuous (21 hours; TSI(50, cont)) or short-term (3 hours; TSI(50, short)) MTX exposure. DNA was isolated from lymphoblasts obtained from cytospin slides. Polymorphisms in methylenetetrahydrofolate reductase (MTHFR 677C>T, MTHFR 1298A>C), methionine synthase (MTR 2756A>G), methionine synthase reductase (MTRR 66A>G), methylenetetrahydrofolate dehydrogenase (MTHFD1 1958G>A), serine hydroxymethyl transferase (SHMT1 1420C>T), thymidylate synthase (TS 2R3R), and the reduced folate carrier (RFC 80G>A) were detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or real-time PCR. Patients with the MTHFR 1298AC variant or the MTRR 66 G-allele showed decreased in vitro MTX sensitivity measured under both test conditions. SHMT1 1420TT homozygotes only showed decreased MTX sensitivity in the TSI(50, cont). In conclusion, polymorphisms in the folate-related genes MTHFR, MTRR, and SHMT1 are related to MTX resistance in pediatric patients with ALL.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15797993 DOI： 10.1182/blood-2004-12-4941
Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113